FDA rejects ivonescimab on PFS-only grounds; oncology updates cover KEYNOTE-C93, pimicotinib, and bladder cancer.
Summary
Speakers analyze the FDA's rejection of Summit/Akeso's ivonescimab, noting a regulatory shift requiring overall survival data over progression-free survival alone. They discuss KEYNOTE-C93, where pembrolizumab showed significant PFS in dMMR endometrial cancer, positioning it for frail patients. The episode covers EMD Serono's pimicotinib approval for TGCT, highlighting competition with Decipher's therapy. Finally, they review updates on AstraZeneca's bladder cancer approval, Moderna's melanoma vaccine, and EU market entries for Chinese PD-1 inhibitors.
Key takeaways
- 1 The data for this combination showed it reduced the risk of death by forty-two percent compared to surgery alone.
Unidentified speaker (speaker_1) · 12:11
Episode sections
- 0:00 – 5:26
Ivonescimab FDA Rejection and Regulatory Shift
The FDA rejected Summit and Akeso's ivonescimab for post-TKI EGFR-mutated NSCLC because it improved progression-free survival (PFS) without demonstrating an overall survival (OS) benefit. The speakers note this establishes a new precedent where PFS alone is insufficient for approval, particularly when trial enrollment is skewed toward Chinese patients with less mature Western data.
- 5:26 – 9:16
KEYNOTE-C93: Pembrolizumab in dMMR Endometrial Cancer
In the KEYNOTE-C93 trial, pembrolizumab monotherapy achieved a median PFS of 38.2 months versus 8.4 months for chemotherapy in dMMR endometrial cancer. The speakers argue this trial is clinically significant not as a replacement for chemo-immunotherapy combos in fit patients, but as a validated, high-efficacy option for frail patients who cannot tolerate combination therapy.
- 9:16 – 11:46
Pimicotinib Approval for TGCT and Market Dynamics
The FDA approved EMD Serono's pimicotinib for tenosynovial giant cell tumor (TGCT), showing a 56% response rate in Phase 3. The speakers highlight that this drug offers a safer, once-daily oral alternative to Decipher's existing therapy, which carries black box liver warnings, intensifying competition in a small US market of 5,000–6,000 patients.
- 11:46 – 15:51
Lightning Round: Bladder, Melanoma, Kidney, and Lung Updates
The segment covers AstraZeneca's Imfinzi + enfortumab vedotin approval for muscle-invasive bladder cancer (42% reduction in death risk), Moderna/Merck's mRNA vaccine data showing a 49% recurrence drop in melanoma, EU positive opinion for Votubia/Lenvima in kidney cancer, and Xingyi's PD-1 inhibitor entering Europe, signaling price competition.
Claims worth verifying
The FDA issued a complete response letter (rejection) to Summit and Akeso for ivonescimab for post-TKI EGFR mutated non-small cell lung cancer.
Unidentified speaker (speaker_0) ·0:52
How to verify: FDA Complete Response Letter database for Summit Therapeutics and Akeso; press releases from both companies dated Nov 2026. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Akeso's stock dropped nearly 23% following the FDA rejection news.
Unidentified speaker (UNKNOWN) ·2:46
How to verify: Stock price history for Akeso (0285.HK) on the Hong Kong Stock Exchange for the trading day following the Nov 10-16, 2026 announcement. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Akeso CEO Michelle Jia blamed the rejection on enrollment timing gaps between Chinese and Western patients.
Unidentified speaker (UNKNOWN) ·3:39
How to verify: Akeso investor presentation or press release following the FDA rejection; news articles quoting CEO Michelle Jia. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
In KEYNOTE-C93, pembrolizumab monotherapy achieved a median progression-free survival of 38.2 months versus 8.4 months for chemotherapy in dMMR endometrial cancer.
Unidentified speaker (speaker_0) ·6:59
How to verify: Publication of KEYNOTE-C93 results in The Lancet; FDA briefing documents for pembrolizumab in endometrial cancer. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
The KEYNOTE-C93 trial compared pembrolizumab to chemotherapy alone, not the current standard of chemo plus immunotherapy.
Unidentified speaker (speaker_1) ·7:29
How to verify: KEYNOTE-C93 trial protocol and published paper in The Lancet; comparison with Ruby trial design. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Pimicotinib received FDA approval for tenosynovial giant cell tumor (TGCT).
Unidentified speaker (speaker_1) ·9:16
How to verify: FDA Drug Approval List for pimicotinib; EMD Serono press release regarding TGCT approval. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Pimicotinib showed a 56% response rate in its Phase 3 trial for TGCT.
Unidentified speaker (UNKNOWN) ·10:31
How to verify: EMD Serono Phase 3 clinical trial data summary; FDA approval package for pimicotinib. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
The US market for TGCT requiring systemic therapy is approximately 5,000–6,000 patients.
Unidentified speaker (speaker_0) ·10:55
How to verify: Epidemiological studies on TGCT prevalence cited in EMD Serono or Decipher materials; market research reports. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Decipher's existing TGCT drug carries black box liver warnings and requires strict safety programs.
Unidentified speaker (UNKNOWN) ·11:11
How to verify: FDA Prescribing Information (Label) for Decipher's TGCT drug (pexidartinib); FDA boxed warning documentation. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
AstraZeneca's Imfinzi combined with enfortumab vedotin reduced the risk of death by 42% in perioperative muscle-invasive bladder cancer.
Unidentified speaker (speaker_1) ·12:11
How to verify: FDA approval package for Imfinzi + enfortumab vedotin in MIBC; published clinical trial data (e.g., EV-302 trial results). For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Do your own research
- Verify the FDA rejection letter for ivonescimab (NDA/BLA number) to confirm the specific deficiency regarding OS data.
- Check Akeso's (2322.HK) stock price movement on 2026-11-16 to quantify the 23% drop cited.
- Review the KEYNOTE-C93 full publication to assess the frail patient subgroup analysis and generalizability.
- Examine Decipher's (DFHC) liver monitoring requirements and black box warnings for their TGCT therapy.
- Confirm AstraZeneca's (AZN) bladder cancer approval details and the hazard ratio for the 42% death risk reduction.
- Monitor EU pricing negotiations for the newly entered Chinese PD-1 inhibitors to assess impact on established immunotherapy margins.
Full transcriptexpand
- 0:00
- Unidentified speaker (speaker_0): You usually expect that when a new drug significantly delays a tumor from growing, well, it's a guaranteed win. That metric is supposed to be the gold standard in oncology development.
- 0:10
- Unidentified speaker (speaker_1): Yeah, you really do.
- 0:11
- Unidentified speaker (speaker_0): Yet the FDA just issued a flat out rejection for a major lung cancer drug that did exactly that. I mean, why is delaying cancer no longer enough to get a treatment approved?
- 0:21
- Unidentified speaker (speaker_1): It's a huge shift in the landscape.
- 0:24
- Unidentified speaker (speaker_0): Welcome to the deep dive.
- 0:25
- Unidentified speaker (UNKNOWN): This
- 0:25
- Unidentified speaker (speaker_0): is your curated breakdown of the Monday morning oncology brief for informed professionals. Whether you're a clinician, an investor, or an industry leader, you're here because you want clarity, not a data dump.
- 0:37
- Unidentified speaker (speaker_1): The regulatory landscape is, you know, it's shifting rapidly underneath our feet. We're watching the standards for clinical success being rewritten in real time.
- 0:45
- Unidentified speaker (UNKNOWN): And
- 0:45
- Unidentified speaker (speaker_0): the stakes for drug developers have really never been higher. So let's look at the biggest shockwave from the brief.
- 0:51
- Unidentified speaker (speaker_1): Yeah, let's get into it.
- 0:52
- Unidentified speaker (speaker_0): We have a complete response letter, which is a formal rejection from the FDA, issued to Summit and Aqueso for their drug Ivanesimab.
- 1:00
- Unidentified speaker (speaker_1): Right.
- 1:01
- Unidentified speaker (speaker_0): This was being tested for post-TKI EGFR mutated non-small cell lung cancer. There is a lot of alphabet soup there. So what exactly is the clinical scenario for these patients? Aaron
- 1:11
- Unidentified speaker (UNKNOWN): Powell
- 1:12
- Unidentified speaker (speaker_1): We're talking about a specific advanced form of lung cancer. Patients usually start on targeted therapies known as TKIs or tyrosine kinase inhibitors. You can think of a TKI as a highly sophisticated smart bomb designed to seek out and disable a very specific mutation in the tumor. Aaron
- 1:29
- Unidentified speaker (UNKNOWN): Powell
- 1:29
- Unidentified speaker (speaker_0): But tumors are notoriously adaptable, aren't
- 1:31
- Unidentified speaker (UNKNOWN): they?
- 1:31
- Unidentified speaker (speaker_0): Aaron
- 1:32
- Unidentified speaker (UNKNOWN): Ross Powell
- 1:32
- Unidentified speaker (speaker_1): They are. Eventually the cancer mutates around the drug, the smart bomb stops working, and the disease progresses.
- 1:38
- Unidentified speaker (UNKNOWN): So
- 1:39
- Unidentified speaker (speaker_1): Ivana Seminab was positioned as the next line of defense for patients who have exhausted those initial TKI options.
- 1:45
- Unidentified speaker (speaker_0): Got it. And the crux of this rejection really comes down to the tension between two clinical concepts. We have PFS, or progression free survival, and OS, overall survival.
- 1:56
- Unidentified speaker (speaker_1): Yeah, that's the core issue here. Aaron
- 1:58
- Unidentified speaker (UNKNOWN): Powell
- 1:58
- Unidentified speaker (speaker_0): I want to make sure we visualize this properly. Let's compare progression progression-free free survival to um clearing a massive traffic jam on your daily commute.
- 2:06
- Unidentified speaker (speaker_1): Okay, I like that analogy. Aaron
- 2:07
- Unidentified speaker (UNKNOWN): Powell
- 2:07
- Unidentified speaker (speaker_0): When the cars finally start moving again, it feels like a huge victory. You know, you're making progress. The tumor isn't growing. But overall survival is whether you actually arrive at the office on time. Aaron
- 2:18
- Unidentified speaker (UNKNOWN): Powell
- 2:19
- Unidentified speaker (speaker_1): Yeah, and the FDOA just ruled that clearing the traffic does not matter if you're still late to the office. The drug successfully delayed the tumor growth in their phase three. trial, but the regulators concluded that a progression-free survival benefit without an overall survival improvement, well, it just doesn't establish a positive benefit risk profile for approval here. Trevor
- 2:38
- Unidentified speaker (UNKNOWN): Burrus
- 2:39
- Unidentified speaker (speaker_0): So they're demanding hard proof that patients are actually living longer. Trevor
- 2:43
- Unidentified speaker (UNKNOWN): Burrus, Jr.
- 2:43
- Unidentified speaker (speaker_1): Yes, regardless of how well the drug keeps the tumor in check. Trevor
- 2:46
- Unidentified speaker (UNKNOWN): Burrus The
- 2:46
- Unidentified speaker (speaker_0): market reaction was brutal and immediate. Following the news, Aquisio a Kisio stock dropped nearly 23%.
- 2:53
- Unidentified speaker (speaker_0): I mean, the financial stakes for these readouts are just massive.
- 2:56
- Unidentified speaker (speaker_1): Massive.
- 2:57
- Unidentified speaker (speaker_0): But what stands out to you about the medical community's reaction? Aaron
- 3:00
- Unidentified speaker (UNKNOWN): Powell
- 3:00
- Unidentified speaker (speaker_1): There's intense debate within the field right now. We saw commentary in the brief from KOL John Wigginton, who cautiously points out the profound tension here. Aaron
- 3:09
- Unidentified speaker (UNKNOWN): Powell
- 3:09
- Unidentified speaker (speaker_0): What was his take?
- 3:10
- Unidentified speaker (speaker_1): He noted that the rejection happened despite a very significant progression. progression-free survival improvement. From a clinical perspective, delaying disease progression has historically been a very meaningful milestone. Aaron
- 3:22
- Unidentified speaker (UNKNOWN): Powell
- 3:22
- Unidentified speaker (speaker_0): Because for decades, keeping the cancer at bay was enough to get a drug to market, while that overall survival data matured.
- 3:28
- Unidentified speaker (speaker_1): Exactly. But then you have the sponsor's defense, which brings in a whole different layer of complexity regarding global clinical trials. Trevor
- 3:35
- Unidentified speaker (UNKNOWN): Burrus, Jr. Right.
- 3:35
- Unidentified speaker (speaker_0): Aquiso's Akiso's CEO, Michelle Ja, pushed back on the FDA's outcome.
- 3:39
- Unidentified speaker (UNKNOWN): She
- 3:40
- Unidentified speaker (speaker_0): blamed the failure on enrollment timing gaps between Chinese and Western patients.
- 3:44
- Unidentified speaker (speaker_1): She also noted that Western clinical sites had limited experience with the drug compared to the trial sites in China. Aaron
- 3:49
- Unidentified speaker (UNKNOWN): Powell
- 3:49
- Unidentified speaker (speaker_0): Which raises the question how does a timing gap in enrollment actually tank an FDA application?
- 3:55
- Unidentified speaker (UNKNOWN): Well,
- 3:55
- Unidentified speaker (speaker_1): it creates a maturity imbalance in the data. The Chinese clinical sites enrolled patients very quickly.
- 4:00
- Unidentified speaker (speaker_0): While the Western sites were much slower.
- 4:02
- Unidentified speaker (speaker_1): Yeah, exactly.
- 4:03
- Unidentified speaker (UNKNOWN): By
- 4:03
- Unidentified speaker (speaker_1): the time the FDA reviewed the data, they were looking at a large pool of Chinese patients whose outcomes were clear. But the data for the Western patients was still just too early to draw conclusions.
- 4:13
- Unidentified speaker (speaker_0): Oh, I see.
- 4:14
- Unidentified speaker (speaker_1): The FDA looks at that imbalance and they hesitate. They need to know how the drug performs in the US population, where the baseline demographics and you know subsequent standards of care might be entirely different from the population in China. Aaron
- 4:26
- Unidentified speaker (UNKNOWN): Powell
- 4:27
- Unidentified speaker (speaker_0): If we connect this to the bigger picture, this establishes a rigid new precedent for the FTA.
- 4:32
- Unidentified speaker (speaker_1): It really does.
- 4:33
- Unidentified speaker (speaker_0): Chinese immuno oncology platforms cannot simply enter the U.S. market relying on progression-free survival alone. If their overseas overall survival data is uncertain, or if the trial demographics are skewed, the door to the U.S. market is firmly closed. Aaron
- 4:49
- Unidentified speaker (UNKNOWN): Powell
- 4:49
- Unidentified speaker (speaker_1): Furthermore, the this rejection means the post TKI lung cancer space remains highly fragmented. The market is still split between established drugs like Tegriso and Ribrovent. Trevor
- 5:00
- Unidentified speaker (UNKNOWN): Burrus, Jr.
- 5:00
- Unidentified speaker (speaker_0): Which are major players. Aaron
- 5:02
- Unidentified speaker (UNKNOWN): Powell
- 5:02
- Unidentified speaker (speaker_1): They are. But they leave a significant gap in treatment sequencing that Ivana Massimab was hoping to fill. Now that gap remains open.
- 5:10
- Unidentified speaker (UNKNOWN): Aaron Powell And
- 5:11
- Unidentified speaker (speaker_0): the regulatory bar to cross it is much higher than anyone anticipated. Aaron
- 5:15
- Unidentified speaker (UNKNOWN): Powell
- 5:15
- Unidentified speaker (speaker_1): Without a doubt.
- 5:16
- Unidentified speaker (speaker_0): Real quick, if you're finding this breakdown useful, um, just hit subscribe so you get the weekly oncology briefing automatically.
- 5:23
- Unidentified speaker (speaker_1): Moving on to the next one.
- 5:25
- Unidentified speaker (speaker_0): Yeah.
- 5:26
- Unidentified speaker (UNKNOWN): So
- 5:26
- Unidentified speaker (speaker_0): regulators are demanding proof that patients are actually living longer, regardless of tumor shrinkage. Which makes you wonder if overall survival and quality of life are the ultimate goals, why are we still so reliant on incredibly harsh chemotherapy combinations when they physically destroy the patient?
- 5:43
- Unidentified speaker (speaker_1): Yeah, that brings us to our next story, where a clinical trial is exploring if we can actually subtract those harsh treatments.
- 5:54
- Unidentified speaker (speaker_1): Right. This trial compared Pembrolizumab MAB monotherapy, so just giving the immunotherapy by itself, against traditional chemotherapy and first. in line DMMR endometrial cancer.
- 6:05
- Unidentified speaker (speaker_0): Okay, let's unpack this because I always get lost in the genetic weeds here. What exactly is failing in a DMMR tumor?
- 6:13
- Unidentified speaker (speaker_1): Let's break down DMMR, which stands for mismatch repair deficient. Every time a cell divides, it has to copy its DNA.
- 6:19
- Unidentified speaker (speaker_0): Sure.
- 6:20
- Unidentified speaker (speaker_1): Think of it like a cell's built built-in in spell check system for that copying process. When the spell checker goes offline, the cell starts accumulating.
- 6:27
- Unidentified speaker (speaker_1): genetic errors.
- 6:28
- Unidentified speaker (speaker_0): Oh, so it leads to a tumor that is just full of typos.
- 6:31
- Unidentified speaker (speaker_1): Yeah, full of typos.
- 6:33
- Unidentified speaker (speaker_0): And when it accumulates all those typos, it starts looking highly abnormal to the immune system?
- 6:38
- Unidentified speaker (speaker_1): It does. And that's where the immunotherapy drug comes in.
- 6:41
- Unidentified speaker (speaker_0): Pember Lizabab acts like a magnifying class. It helps the body's immune system clearly spot all those typos and attack the rogue cells. Aaron
- 6:48
- Unidentified speaker (UNKNOWN): Powell
- 6:49
- Unidentified speaker (speaker_1): The mechanism is highly targeted. you know, leveraging the tumor zone instability against it.
- 6:54
- Unidentified speaker (UNKNOWN): And
- 6:54
- Unidentified speaker (speaker_1): that brings us to the trial results, which were gathered from over 350 patients across multiple countries.
- 6:59
- Unidentified speaker (speaker_0): The numbers here are striking. Patients on Pemberluzimab had a progression free survival of 38.2 months. Compare that to just 8.4 months for those on standard chemotherapy.
- 7:11
- Unidentified speaker (speaker_2): The difference is night and day.
- 7:12
- Unidentified speaker (speaker_0): What does it look like for the person sitting in the clinic?
- 7:15
- Unidentified speaker (UNKNOWN): They
- 7:15
- Unidentified speaker (speaker_0): went roughly two and a half years longer without their cancer growing just by using the immunotherapy alone.
- 7:21
- Unidentified speaker (speaker_1): It's a huge shift in their daily life.
- 7:23
- Unidentified speaker (speaker_0): But I have to push back on this trial's design. The massive caveat here is the comparator arm.
- 7:29
- Unidentified speaker (speaker_1): Okay.
- 7:29
- Unidentified speaker (speaker_0): The trial compared immunotherapy to chemotherapy alone. That is not the current standard of care. Trials like Ruby have already established that the standard for these patients. is chemotherapy plus immunotherapy.
- 7:41
- Unidentified speaker (speaker_1): That's true.
- 7:42
- Unidentified speaker (speaker_0): So did they just spend years running a massive trial to beat an outdated benchmark?
- 7:47
- Unidentified speaker (speaker_1): This raises an important question about how we view standard of care. It's not entirely outdated if you look at who this treatment is actually for.
- 7:54
- Unidentified speaker (speaker_3): What do you mean?
- 7:55
- Unidentified speaker (speaker_1): You're correct that for a fit, healthy patient, chemotherapy plus immunotherapy remains the gold standard. The keynote C93 trial does not challenge that combination directly. If a patient can tolerate the combo, they should get the combo.
- 8:09
- Unidentified speaker (speaker_3): So
- 8:09
- Unidentified speaker (speaker_0): who is this for then?
- 8:11
- Unidentified speaker (speaker_1): You're missing the 20 to 30% of patients who physically cannot survive that combination. Endometrial cancer often affects older women who may have significant comorbidities, heart issues, severe diabetes, or kidney problems.
- 8:24
- Unidentified speaker (speaker_0): Oh, I see.
- 8:25
- Unidentified speaker (UNKNOWN): The
- 8:25
- Unidentified speaker (speaker_1): true value of keynote. C93 is that it completely reframes the chemo-free option. It legitimizes using immunotherapy alone for patients who are simply too frail to endure the severe side effects of chemotherapy.
- 8:38
- Unidentified speaker (speaker_0): Or who actively decline it because of the impact on their quality of life.
- 8:42
- Unidentified speaker (speaker_1): Yeah. It provides hard evidence that they have a highly effective alternative.
- 8:47
- Unidentified speaker (speaker_0): So in this case, returning to our commute analogy, we aren't just clear. clearing the traffic jam. We're giving the frailest patients a much smoother, safer ride to the office without destroying the vehicle along the way. Aaron
- 8:59
- Unidentified speaker (UNKNOWN): Powell
- 8:59
- Unidentified speaker (speaker_1): That is the perfect way to look at it. The focus shifts from maximum aggression to optimizing the patient's capacity to handle the treatment.
- 9:07
- Unidentified speaker (speaker_0): That focus on sparing patients from brutal side effects leads us perfectly into our next story about a rare debilitating condition where the market is suddenly heating up.
- 9:16
- Unidentified speaker (speaker_1): Yeah, the FDA just approved a drug called pimicotinib for a condition called tenosynovial giant cell tumor, or TGCT.
- 9:23
- Unidentified speaker (speaker_0): Here's where it gets really interesting. TGCT is technically a benign tumor. It does not spread to other organs like a typical cancer. Aaron Powell
- 9:31
- Unidentified speaker (speaker_1): Right. But these are highly aggressive tumors that grow inside the joints, often the knee or the hip, and they severely limit. a person's mobility.
- 9:40
- Unidentified speaker (speaker_0): They cause intense swelling, stiffness, and pain. Patients often require repeated destructive surgeries just to maintain basic function.
- 9:48
- Unidentified speaker (speaker_1): And unfortunately, the tumors frequently grow back. So the underlying mechanism for pimicotinib is that it acts as a CSF1R kinase inhibitor. Aaron
- 9:59
- Unidentified speaker (UNKNOWN): Powell
- 9:59
- Unidentified speaker (speaker_0): Let's explain how that works in the joint. Think of the tumor environment like a rogue factory.
- 10:04
- Unidentified speaker (speaker_1): A rogue factory producing inflammatory cells that gather in the joint and cause all that severe swelling.
- 10:10
- Unidentified speaker (speaker_0): Yeah, and the CSF1R is essentially the chemical signal that keeps the factory running.
- 10:15
- Unidentified speaker (speaker_2): It's the power supply.
- 10:16
- Unidentified speaker (UNKNOWN): So
- 10:17
- Unidentified speaker (speaker_0): this drug acts like cutting the power supply to that very specific factory. It shuts down the chemical signal that tells those destructive cells to gather, stopping the tumor from maintaining itself.
- 10:27
- Unidentified speaker (speaker_1): And shutting down that signal produces significant clinical results.
- 10:31
- Unidentified speaker (UNKNOWN): The
- 10:31
- Unidentified speaker (speaker_0): phase three trial showed a 56% response rate.
- 10:34
- Unidentified speaker (speaker_1): That's massive.
- 10:35
- Unidentified speaker (speaker_0): In practical terms, more than half of the patients who took this drug saw their joint tumors visibly shrink, and they reported major improvements in pain and stiffness.
- 10:44
- Unidentified speaker (speaker_1): Which is incredible for them.
- 10:45
- Unidentified speaker (speaker_0): But this raises an important point about market dynamics. This approval creates intense intercalateral. intraclass competition in a very small space.
- 10:53
- Unidentified speaker (speaker_1): How small are we talking?
- 10:55
- Unidentified speaker (speaker_0): We're talking about a US market of only about 5,000 to 6,000 patients, requiring systemic therapy. Previously, this entire space was monopolized by a single company, De Cipher. Decipher's first drug for this condition was approved back in 2019, but it carried heavy baggage, didn't it?
- 11:11
- Unidentified speaker (UNKNOWN): Aaron Powell
- 11:11
- Unidentified speaker (speaker_1): It did. It carried heavy black box liver warnings. Patients had to enroll in strict, burdensome safety programs. Aaron
- 11:18
- Unidentified speaker (UNKNOWN): Ross
- 11:18
- Unidentified speaker (speaker_1): Powell
- 11:18
- Unidentified speaker (speaker_0): Requiring constant blood tests to monitor their liver enzymes, right?
- 11:22
- Unidentified speaker (speaker_1): Yeah. It caused a lot of anxiety for patients who were already dealing with chronic pain. Aaron
- 11:25
- Unidentified speaker (UNKNOWN): Powell
- 11:26
- Unidentified speaker (speaker_1): But
- 11:26
- Unidentified speaker (speaker_0): Pimicotin have enters the market as a once daily pill without those heavy safety restrictions. Aaron
- 11:30
- Unidentified speaker (UNKNOWN): Ross Powell
- 11:30
- Unidentified speaker (speaker_1): And without the black box warning.
- 11:32
- Unidentified speaker (speaker_0): It sets up a fierce commercial battle for a very small, defined patient population. Aaron
- 11:37
- Unidentified speaker (UNKNOWN): Powell
- 11:37
- Unidentified speaker (speaker_1): Giving clinicians a much cleaner safety profile to work with.
- 11:41
- Unidentified speaker (speaker_0): It's a massive quality of life upgrade for patients who've been dealing with joint destruction for years.
- 11:45
- Unidentified speaker (speaker_1): Absolutely.
- 11:46
- Unidentified speaker (speaker_0): Okay. Let's shift gears explicitly to a rapid-fire rundown of the remaining essential headlines. There is a lot of movement across different tumor types this week.
- 11:55
- Unidentified speaker (speaker_1): Starting in bladder cancer, AstraZeneca's infinzy combined with InfortimaBetatine secured FDA approval early.
- 12:03
- Unidentified speaker (speaker_0): This is for perioperative MIBC, which stands for muscle invasive bladder cancer, meaning the cancer has grown into the deeper layers of the bladder wall.
- 12:11
- Unidentified speaker (speaker_1): Yeah, making it much harder to treat with surgery alone. The data for this combination showed it reduced the risk of death by forty-two percent compared to surgery alone.
- 12:20
- Unidentified speaker (speaker_0): That is a massive survival benefit in a setting where recurrence rates post-surgery are notoriously high.
- 12:27
- Unidentified speaker (speaker_1): Definitely. Moving to melanoma, Moderna and Merck published their phase three mRNA cancer vaccine data in the New England Journal of Medicine.
- 12:35
- Unidentified speaker (speaker_0): And the vaccine, combined with immunotherapy, showed a 49% drop in cancer recurrence. Wait, cutting recurrence in half. Are we finally seeing the COVID-era mRNA technology truly cross over and prove its worth in oncology?
- 12:49
- Unidentified speaker (speaker_1): We are. This data provides peer-reviewed validation that you can train the immune system using mRNA to recognize specific tumor neoantigens.
- 12:58
- Unidentified speaker (speaker_0): It's a major milestone for personalized cancer vaccines. Over in kidney cancer, EU regulators adopted a positive opinion for the WillyReg and Lenvima combination.
- 13:09
- Unidentified speaker (speaker_1): This offers a new highly targeted option for patients after initial immunotherapy combinations fail.
- 13:15
- Unidentified speaker (speaker_0): It hits the cancer's blood supply and oxygen sensing pathways simultaneously.
- 13:19
- Unidentified speaker (speaker_1): Which is a novel approach for advanced renal cell carcinoma.
- 13:22
- Unidentified speaker (speaker_0): In lung cancer, xyrin just became the second Chinese PD1 inhibitor to get a positive EU regulatory nod.
- 13:29
- Unidentified speaker (speaker_1): And just a reminder: a PD1 inhibitor is a foundational immunotherapy that takes the brakes off the immune system so it can attack the cancer.
- 13:37
- Unidentified speaker (speaker_0): Seeing a second Chinese PD1 inhibitor. enter Europe signals heavy upcoming price competition.
- 13:43
- Unidentified speaker (speaker_1): These companies are likely to compete aggressively on cost. That could really disrupt the pricing models for established immunotherapies in the European market.
- 13:55
- Unidentified speaker (speaker_0): This is a bio similar to the blockbuster drug Pergeta, Pergetta, which is used heavily in HER2-positive HER2 positive breast cancer.
- 14:01
- Unidentified speaker (UNKNOWN): However,
- 14:02
- Unidentified speaker (speaker_1): a patent set settlement delays the U.S. launch until 2028.
- 14:05
- Unidentified speaker (speaker_0): So while the approvals on the books, current market shares for the branded drug are protected for a few more years.
- 14:11
- Unidentified speaker (speaker_1): Exactly.
- 14:11
- Unidentified speaker (UNKNOWN): So
- 14:12
- Unidentified speaker (speaker_0): what does this all mean? When we step back and look at the three major stories we covered: the Ivanesum abd rejection, the keto trial in endometrial cancer, and the new pill for joint tumors, a clear picture emerges of where oncology is heading.
- 14:25
- Unidentified speaker (UNKNOWN): The
- 14:25
- Unidentified speaker (speaker_1): field is experiencing a profound fracturing in how we define clinical success.
- 14:30
- Unidentified speaker (speaker_0): On one hand, the regulatory bar is ruthlessly high.
- 14:34
- Unidentified speaker (UNKNOWN): As
- 14:35
- Unidentified speaker (speaker_0): we saw with the lung cancer rejection, delaying tumor growth is no longer sufficient.
- 14:40
- Unidentified speaker (speaker_1): Regulators demand hard, indisputable overall survival data.
- 14:44
- Unidentified speaker (speaker_0): Yet simultaneously, the field is fine-tuning treatments to spare frail patients, like we saw with the chemo-free option in endometrial cancer.
- 14:53
- Unidentified speaker (speaker_1): And we're seeing intense, patient-friendly competition driving innovation in rare diseases, moving away from toxic drugs with black box warnings toward cleaner daily pills. Aaron Powell
- 15:04
- Unidentified speaker (speaker_0): Success is no longer a one-size-fits-all metric. It is heavily fractured based on patient fragility, geopolitical trial data, and market saturation.
- 15:13
- Unidentified speaker (speaker_1): Which leaves you to wonder about the future of drug development.
- 15:17
- Unidentified speaker (speaker_0): Yeah. As we move toward an era where frail patients get chemo-free options and rare diseases get highly targeted safer pills, will progression-free survival become a totally obsolete metric in the next five years? Or will the FDA be forced to walk back this ruthlessly high bar as drug development costs skyrocket
- 15:37
- Unidentified speaker (speaker_0): and companies struggle to prove? overall survival.
- 15:40
- Unidentified speaker (speaker_1): It's definitely something to watch as the market evolves.
- 15:43
- Unidentified speaker (speaker_0): For sure. If you enjoyed this deep dive, please subscribe and share it with a colleague. And we will be back next week.